$COCP

Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jun 9, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$COCP
Neutral
medium confidence
Mentioned
$COCP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The disclosure provides concrete incentive structure (salary, bonus, option strike at $1.05, and acceleration triggers) that may influence expectations for execution and potential M&A/strategic actions, but it does not provide new operating metrics.

02

Market read

Traders may reassess COCP’s governance/execution outlook due to the CEO transition, but the filing lacks pipeline or financial catalysts.

03

What to watch

Investors may focus on whether the incoming CEO’s prior GI-focused background translates to Cocrystal’s current development priorities, but the filing does not specify strategy changes.

Relevance 6/10Novelty 6/10Timing: effective immediately (CEO appointment dated June 3, 2026; filed June 9, 2026)

Background

The 8-K (Item 5.02) reports a CEO appointment and related compensatory arrangements, replacing the company’s co-CEOs.

Company-level read

Ticker impact

$COCPNeutralMedium confidence
Context

Cocrystal Pharma appointed James Sapirstein as CEO and disclosed his base salary, bonus, and 10-year option grants with vesting/acceleration terms.

Expected impact

Likely modest, sentiment-neutral reaction unless investors view the CEO change as a clear strategic inflection.

Evidence & confidence

The filing is a primary disclosure (8-K Item 5.02) but it does not include clinical/product updates or financial guidance; impact is mainly governance/expectations rather than fundamentals.

Market effects

Biopharma governance changes can affect perceived pipeline execution quality, but no sector-wide regulatory/clinical catalyst is disclosed here.

No specific regional market linkage beyond US-listed small-cap biotech sentiment.

No direct global operational or partnership update is provided.

Counterpoint

Equity compensation and vesting acceleration are standard; without pipeline/clinical milestones, the market may discount the CEO change as non-informative.

Key entities

  • Cocrystal Pharma, Inc.

    Nasdaq-listed biopharmaceutical company filing the 8-K regarding CEO appointment and compensation.

  • James Sapirstein

    Appointed Chief Executive Officer effective immediately; receives base salary, performance bonus, and option grants with vesting/acceleration terms.

  • Sam Lee

    Former co-CEO; continues as President and Chief Scientific Officer.

  • James Martin

    Former co-CEO; continues as Chief Financial Officer and signs the filing.

Related articles

$CRWVHighAI 9/10

CRWV Stock Drops to $80 on Soaring Costs as CoreWeave Plans $3 Billion Convertible Debt Offering

CoreWeave (CRWV) shares dropped nearly 5% to below $80 after announcing a $3 billion convertible debt offering and a potential $2.92 billion equity raise to fund infrastructure expansion. The company aims to use proceeds for growth and to offset shareholder dilution, but the financing plans highlight its capital-intensive expansion and dependence on external funding.

$GEHighAI 8/10

GE Looks 15.6% Overvalued on GF Value™ as Boeing 777X Engine Upd

GE Aerospace's CFO addressed durability concerns about the GE9X engine, assuring no delay for Boeing's 777X. The company redesigned the component and began shipping updated engines. GE's stock is trading at $313.47, 15.6% above its GF Value™ of $271.20, indicating modest overvaluation. The company's GF Score™ is 76/100, with strong momentum but mixed insider and guru activity.

$CACCMedAI 8/10

Credit Acceptance settlement provides $700 million in debt relief, restitution and penalties

Credit Acceptance Corp. agreed to a $700M settlement, including $630M in debt relief, $60M in restitution, and $15.5M in penalties. The deal, led by New York AG Letitia James and 39 other states, covers 55,000 borrowers. The company must change its default handling and add-on product sales practices. The settlement resolves allegations of predatory lending and misrepresentation of loan terms.

$JPMMedAI 8/10

JPMorgan Chase (JPM) Commits $750 Billion to Rebuilding America’s Housing Supply

JPMorgan Chase (JPM) plans to invest $750 billion by 2035 to boost U.S. housing supply, including financing 1 million affordable units and aiding 500,000 homebuyers. The bank reported record Q2 net income of $21.2 billion, supporting its expanded housing efforts. Potential benefits include increased mortgage revenue and customer relationships, but risks include credit exposure and market conditions.

$AXONMedAI 8/10

Axon Rebounded 6% Wednesday. Here’s What Could Drive the Stock Through 2026

Axon Enterprise's stock rebounded 6% to $468 on Wednesday after a 10% drop following a $1 billion convertible notes offering. The company expects 32-34% revenue growth in 2026, with strong Q4 growth anticipated. Analysts maintain bullish targets, citing Axon's faster expansion compared to competitors like Motorola Solutions. The stock has an implied upside of 56% based on a valuation model target of $706.

$CRWVHighAI 9/10

Why CoreWeave Stock Dived by More Than 5% Today

CoreWeave (CRWV) stock fell over 5% after announcing two fundraising measures: an at-the-market stock offering of up to 35 million shares and a $3 billion convertible senior notes issue. The company plans to use proceeds for financing flexibility, credit profile improvement, and general corporate purposes. CoreWeave has $43.5 billion in long-term debt and added $25 billion in new customer commitments this quarter.